Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2171-2026

ZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040A Recall

ZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040A

FDA recall Class II

Ongoing

FDA lists this Class II recall for ZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040A. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2171-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Apr 1, 2026
FDA report date
May 20, 2026
Quantity in commerce
359 units
Distribution
See key details
FDA cause
Labeling Change Control

What is being recalled?

ZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040A

Affected model & UDI checker

Search the exact identifiers published for Z-2171-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
RK040AZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040ACheck source noticeNot specified
Not specifiedZYMUTEST HIA IgG, in vitro diagnostic ELISA kit, Ref. RK040ACheck source notice03663537018763
FDA code information

UDI-DI: 03663537018763; Lot Number: FD1265

View the original FDA recall notice

Why was this product recalled?

Kits from lot FD1265 had been packaged on 17 October 2024 and put on the market with an outdated flyer (8 October 2024), containing incorrect values for the positive control.

What actions did Aniara Diagnostica LLC take?

A Field Corrective Action notification letter dated 3/30/26 was sent to customers. Actions implemented by HYPHEN BioMed: -Confirmation of the existence of a flyer discrepancy affecting 95 kits from lot FD1265. - Request for quarantine of the affected kits in US agent warehouse. -Coordination with US agent for notification of the impacted end users. -investigation to define the root cause and to establish corrective and preventive actions. Actions to be implemented by the end user: 1. Check the TAV flyer included in their kit. - If the flyer matches the correct version (dated 18 October 2024) - No action is required. - If the flyer corresponds to the incorrect version (dated I October 2024) - proceed to step 2 2. Destroy the incorrect TAV flyer. The outdated flyer included in the kit must be immediately removed and destroyed, as well as any paper or electronic copy that could have been done in end-user facility, to prevent further use. 3. Replace the incorrect flyer with the corrected version. Use the corrected TAV flyer provided with this notice for all future testing 4. Return the completed and signed form to your local distributor before April 15th, 2026. For any question or information regarding this notification, please contact vigilance team, by email at [email protected].

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology